Function and Therapeutic Advances of Chemokine and Its Receptor in Nonalcoholic Fatty Liver Disease

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2018 Dec 22

PMID 30574191

Citations 16

Authors

Wei Chen

Jing Zhang

Hui-Ning Fan

Jin-Shui Zhu

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of hepatic pathology, ranging from simple accumulation of fat in its most benign form, steatohepatitis, to cirrhosis in its most advanced form. The prevalence of NAFLD is 20-30% in adults, and 10-20% of patients with NAFLD progress to nonalcoholic steatohepatitis (NASH) which is predicted to be the leading cause of liver transplantation over the next 10 years. Therefore, it is essential to explore effective diagnostic and treatment strategies for NAFLD patients. Chemokines are a family of small and highly conserved proteins (molecular weight ranging from 8 to 12 kDa) involved in regulating the migration and activities of hepatocytes, Kupffer cells (KCs), hepatic stellate cells (HSCs), endothelial cells and circulating immune cells. Accumulating data show that chemokine and its receptor act vital roles in the pathogenesis of NAFLD. Herein, we summarize the involvement of the chemokine and its receptor in the pathogenesis of NAFLD and explore the novel pharmacotherapeutic avenues for patients with NAFLD.

Citing Articles

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease.

Cho Y, Kwon Y, Hwang S Liver Res. 2025; 7(1):16-25.

PMID: 39959694 PMC: 11791820. DOI: 10.1016/j.livres.2022.06.001.

A multi-omic landscape of steatosis-to-NASH progression.

Xiang L, Li X, Luo Y, Zhou B, Liu Y, Li Y Life Metab. 2025; 1(3):242-257.

PMID: 39872077 PMC: 11749464. DOI: 10.1093/lifemeta/loac034.

Metabolic regulation of the immune system in health and diseases: mechanisms and interventions.

Hu T, Liu C, Lei M, Zeng Q, Li L, Tang H Signal Transduct Target Ther. 2024; 9(1):268.

PMID: 39379377 PMC: 11461632. DOI: 10.1038/s41392-024-01954-6.

Association of IL-8 and CXCR2 with AST/ALT Ratio in Liver Abnormalities Screening during Oxidative Stress Injury Caused by VCM.

Dong Y, Wang X, Hu W, Wang X, Bian H, Zhang W J Toxicol. 2024; 2024:1951046.

PMID: 39108287 PMC: 11303046. DOI: 10.1155/2024/1951046.

MicroRNAs and Nonalcoholic Steatohepatitis: A Review.

Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Kobara H Int J Mol Sci. 2023; 24(19).

PMID: 37833930 PMC: 10572537. DOI: 10.3390/ijms241914482.

References

Zlotnik A, Yoshie O . Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12(2):121-7. DOI: 10.1016/s1074-7613(00)80165-x. View

Youn B, Mantel C, Broxmeyer H . Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2001; 177:150-74. DOI: 10.1034/j.1600-065x.2000.17701.x. View

Mackay C . Chemokines: immunology's high impact factors. Nat Immunol. 2001; 2(2):95-101. DOI: 10.1038/84298. View

Efsen E, Grappone C, Defranco R, Milani S, Romanelli R, Bonacchi A . Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol. 2002; 37(1):39-47. DOI: 10.1016/s0168-8278(02)00065-x. View

Clark-Lewis I, Mattioli I, Gong J, Loetscher P . Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem. 2002; 278(1):289-95. DOI: 10.1074/jbc.M209470200. View

Mukaida N . Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2003; 284(4):L566-77. DOI: 10.1152/ajplung.00233.2002. View

Koch A, Polverini P, Kunkel S, Harlow L, DiPietro L, Elner V . Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992; 258(5089):1798-801. DOI: 10.1126/science.1281554. View

Xu H, Barnes G, Yang Q, Tan G, Yang D, Chou C . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112(12):1821-30. PMC: 296998. DOI: 10.1172/JCI19451. View

Rot A, von Andrian U . Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004; 22:891-928. DOI: 10.1146/annurev.immunol.22.012703.104543. View

10.

Fujii H, Itoh Y, Yamaguchi K, Yamauchi N, Harano Y, Nakajima T . Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun. 2004; 322(3):1052-8. DOI: 10.1016/j.bbrc.2004.07.207. View

11.

Geissmann F, Cameron T, Sidobre S, Manlongat N, Kronenberg M, Briskin M . Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005; 3(4):e113. PMC: 1073691. DOI: 10.1371/journal.pbio.0030113. View

12.

Aghi M, Cohen K, Klein R, Scadden D, Chiocca E . Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006; 66(18):9054-64. DOI: 10.1158/0008-5472.CAN-05-3759. View

13.

Hubscher S . Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006; 49(5):450-65. DOI: 10.1111/j.1365-2559.2006.02416.x. View

14.

Wasmuth H, Zaldivar M, Berres M, Werth A, Scholten D, Hillebrandt S . The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol. 2007; 48(2):208-15. DOI: 10.1016/j.jhep.2007.09.008. View

15.

Guilherme A, Virbasius J, Puri V, Czech M . Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9(5):367-77. PMC: 2886982. DOI: 10.1038/nrm2391. View

16.

Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K . Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol. 2008; 28(12):2195-201. DOI: 10.1161/ATVBAHA.108.168633. View

17.

Yang S, IglayReger H, Kadouh H, Bodary P . Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia. 2009; 52(5):972-81. DOI: 10.1007/s00125-009-1309-8. View

18.

Wasmuth H, Lammert F, Zaldivar M, Weiskirchen R, Hellerbrand C, Scholten D . Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009; 137(1):309-19, 319.e1-3. PMC: 2892869. DOI: 10.1053/j.gastro.2009.03.053. View

19.

Matsuo Y, Raimondo M, Woodward T, Wallace M, Gill K, Tong Z . CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 2009; 125(5):1027-37. DOI: 10.1002/ijc.24383. View

20.

Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N . CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009; 50(1):185-97. PMC: 2705470. DOI: 10.1002/hep.22952. View